{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T20:34:06Z","timestamp":1780432446058,"version":"3.54.1"},"reference-count":39,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2021,2,14]],"date-time":"2021-02-14T00:00:00Z","timestamp":1613260800000},"content-version":"vor","delay-in-days":44,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["A&amp;D Transl Res &amp; Clin Interv"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A Phase II proof of concept (POC) randomized clinical trial was conducted to evaluate the effects of rasagiline, a monoamine oxidase B (MAO\u2010B) inhibitor approved for Parkinson disease, in mild to moderate Alzheimer's disease (AD). The primary objective was to determine if 1\u00a0mg of rasagiline daily for 24\u00a0weeks is associated with improved regional brain metabolism (fluorodeoxyglucose\u2013positron emission tomography [FDG\u2010PET]) compared to placebo. Secondary objectives included measurement of effects on tau PET and evaluation of directional consistency of clinical end points.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a double\u2010blind, parallel group, placebo\u2010controlled, community\u2010based, three\u2010site trial of 50 participants randomized 1:1 to receive oral rasagiline or placebo (NCT02359552). FDG\u2010PET was analyzed for the presence of an AD\u2010like pattern as an inclusion criterion and as a longitudinal outcome using prespecified regions of interest and voxel\u2010based analyses. Tau PET was evaluated at baseline and longitudinally. Clinical outcomes were analyzed using an intention\u2010to\u2010treat (ITT) model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Fifty patients were randomized and 43 completed treatment. The study met its primary end point, demonstrating favorable change in FDG\u2010PET differences in rasagiline versus placebo in middle frontal (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u00a00.025), anterior cingulate (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u00a00.041), and striatal (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u00a00.023) regions. Clinical measures showed benefit in quality of life (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u00a00.04). Digit Span, verbal fluency, and Neuropsychiatric Inventory (NPI) showed non\u2010significant directional favoring of rasagiline; no effects were observed in Alzheimer's Disease Assessment Scale\u2010Cognitive Subscale (ADAS\u2010cog) or activities of daily living. Rasagiline was generally well tolerated with low rates of adverse events and notably fewer neuropsychiatric symptoms in the active treatment group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>These outcomes illustrate the potential benefits of rasagiline on clinical and neuroimaging measures in patients with mild to moderate AD. Rasagiline appears to affect neuronal activity in frontostriatal pathways, with associated clinical benefit potential warranting a more fully powered trial. This study illustrated the potential benefit of therapeutic repurposing and an experimental medicine proof\u2010of\u2010concept design with biomarkers to characterize patient and detect treatment response.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/trc2.12106","type":"journal-article","created":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T08:36:56Z","timestamp":1613464616000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer's dementia"],"prefix":"10.1002","volume":"7","author":[{"given":"Dawn C.","family":"Matthews","sequence":"first","affiliation":[{"name":"ADM Diagnostics, Inc.  Northbrook Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Ritter","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Lou Ruvo Center for Brain Health  Las Vegas Nevada USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald G.","family":"Thomas","sequence":"additional","affiliation":[{"name":"Department of Family Medicine and Public Health UCSD  La Jolla California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randolph D.","family":"Andrews","sequence":"additional","affiliation":[{"name":"ADM Diagnostics, Inc.  Northbrook Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana S.","family":"Lukic","sequence":"additional","affiliation":[{"name":"ADM Diagnostics, Inc.  Northbrook Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Revta","sequence":"additional","affiliation":[{"name":"Alzheimer's Disease Cooperative Study University of California San Diego School of Medicine  La Jolla California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jefferson W.","family":"Kinney","sequence":"additional","affiliation":[{"name":"Department of Brain Health University of Nevada Las Vegas  Las Vegas Nevada USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babak","family":"Tousi","sequence":"additional","affiliation":[{"name":"Neurologic Institute Cleveland Clinic  Cleveland Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B.","family":"Leverenz","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Lou Ruvo Center for Brain Health  Cleveland Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Fillit","sequence":"additional","affiliation":[{"name":"Alzheimer's Drug Discovery Foundation  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Zhong","sequence":"additional","affiliation":[{"name":"CNS Innovations LLC  Henderson Nevada USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard H.","family":"Feldman","sequence":"additional","affiliation":[{"name":"Department of Neurosciences Alzheimer's Disease Cooperative Study San Diego University of California  La Jolla California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Cummings","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Lou Ruvo Center for Brain Health  Las Vegas Nevada USA"},{"name":"Department of Brain Health Chambers\u2010Grundy Center for Transformative Neuroscience School of Integrated Health Sciences University of Nevada Las Vegas  Nevada USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,2,14]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/alzrt269"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-0082(02)00011-4"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2010-100150"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23926"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2014.00180"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20764"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23738"},{"issue":"8","key":"e_1_2_11_9_1","first-page":"784","article-title":"Effect of selegiline on cognitive functions in Parkinson's disease","volume":"47","author":"Dixit SN","year":"1999","journal-title":"J Assoc Physicians India"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00216016"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199704243361704"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(99)80017-0"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-161309"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008239"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21345"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-009-1714-1"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2010.02.064"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.5.738"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-170833"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-006-0127-z"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2017.05.058"},{"issue":"3","key":"e_1_2_11_22_1","first-page":"748","article-title":"18F\u2010AV\u20101451\u2010A05 investigators. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition","volume":"140","author":"Pontecorvo MJ","year":"2017","journal-title":"Brain"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz090"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trci.2016.02.004"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/120.12.2187"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S49261"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-7908-2604-3_10"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.200006"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1214\/13-AOAS713"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812840"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2011.03.002"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4020-5779-3_2"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.10372"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awh539"},{"issue":"10","key":"e_1_2_11_35_1","first-page":"1618","article-title":"In vivo measurement of brain monoamine oxidase B occupancy by rasagiline, using (11)C\u2010l\u2010deprenyl and PET","volume":"46","author":"Freedman NM","year":"2005","journal-title":"J Nucl Med"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2019.102091"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awx046"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.12917"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199704243361704"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70043-0"}],"container-title":["Alzheimer's &amp; Dementia: Translational Research &amp; Clinical Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/trc2.12106","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/trc2.12106","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/trc2.12106","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T12:13:15Z","timestamp":1761480795000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1002\/trc2.12106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.1002\/trc2.12106"],"URL":"https:\/\/doi.org\/10.1002\/trc2.12106","archive":["Portico"],"relation":{},"ISSN":["2352-8737","2352-8737"],"issn-type":[{"value":"2352-8737","type":"print"},{"value":"2352-8737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"2020-09-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e12106"}}